Humana · Abecma · US health-plan appeal rights

Abecma denied as duplicate or overlapping therapy by Humana?

Q: How long do I have to appeal a Humana Abecma denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

FDA-approved indication: r/r multiple myeloma after >=2 prior lines including IMiD + PI + anti-CD38 mAb (Apr 2024 2L+ expansion via KarMMa-3) OR after >=4 prior lines (Mar 2021). Age >=18. ECOG 0-1. LVEF >=45%, CrCl >=45, AST/ALT <2.5x ULN, total bili <1.5x ULN, ANC >=1000, plt >=50K. No prior BCMA-directed CAR-T. Administered at FACT-accredited REMS-certified ATC. Bridging + Flu/Cy LD (Flu 30 + Cy 300 mg/m² x 3 d) bundled.

Source policy: Humana Medical Coverage Policy — Idecabtagene Vicleucel (Abecma)

What works in the appeal

KarMMa-3 (Rodriguez-Otero NEJM 2023;388:1002) — Abecma vs SOC standard regimens in 2L+ triple-class-exposed MM with PFS HR 0.49 → FDA Apr 4 2024 2L+ expansion. NCCN MM v3.2024 lists both Abecma and Carvykti as 2L+ options; product choice is per treating physician + slot availability + apheresis logistics — payer cannot mandate one BCMA CAR-T over another. KarMMa-3 entry required prior IMiD + PI + anti-CD38 with refractoriness to last regimen — matches Apr 2024 label exactly. Bridging is inherent to CAR-T pathway per NCCN MM v3.2024 + ASTCT 2024 consensus. CMS NCD 110.24 covers FDA-approved indications.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other denial reasons for Humana Abecma

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.